Researcher access
Sign in to view this compound
Stemcode Peptides supplies research-use-only compounds to registered researchers aged 21 or over. Register in under a minute, or sign in, to continue.
Tablets
MK-677 Tablets (Ibutamoren)
MK-677 (Ibutamoren) oral tablets, 15mg per tablet, 60 tablets (900mg total). For research use only.
Est. delivery
Also Known As: Ibutamoren, MK-0677
MK-677 is also known as Ibutamoren or MK-0677 — these names refer to the same orally active small-molecule ghrelin receptor (GHS-R1a) agonist studied in growth hormone and IGF-1 research. It is a small molecule, not a peptide and not a SARM. For research use only.
Certificate of Analysis
Reference Chemistry
Chemical Specification
- CAS #
- 159634-47-6
- Molecular Formula
- M.W.
- 528.7 g/mol
- PubChem CID
- 178024
- InChIKey
- UMUPQWIGCOZEOY-JOCHJYFZSA-N
- IUPAC name
- 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
Reference chemistry verified against PubChem. HPLC purity is the most recent reported value from an on-file COA for this product.
RESEARCH USE ONLY — not for human or animal consumption. Not for diagnostic or therapeutic use.
Description
MK-677, also known as Ibutamoren or MK-0677, is an orally active small-molecule growth hormone secretagogue built on a spiroindoline scaffold. It acts as a ghrelin mimetic — an agonist of the growth hormone secretagogue receptor GHS-R1a. In published clinical research, once-daily oral administration enhanced pulsatile growth hormone secretion and raised serum IGF-1 concentrations in a dose-dependent manner. Unlike most compounds in this catalog, MK-677 is a small molecule, not a peptide. Supplied as 15mg tablets, 60 per container. For research use only.
MK-677 is also stocked as a measured oral solution, MK-677 Liquid at 25mg per mL, for dose-response designs that draw a volume rather than split a tablet.
Research Background
MK-677 has one of the deepest clinical literatures of any growth hormone secretagogue. Chapman et al. (1996) reported that daily oral MK-677 enhanced pulsatile GH release and restored IGF-1 to young-adult ranges in healthy older subjects. A 2-year randomized trial in healthy older adults (Nass et al., Annals of Internal Medicine, 2008) found increased GH and IGF-1 levels and increased fat-free mass, alongside increased fasting glucose and decreased insulin sensitivity. Other trials examined nitrogen balance during caloric restriction, bone-turnover markers and bone mineral density, sleep architecture, and appetite-related ghrelin signaling.
This product is intended strictly for laboratory research use only and is not for human consumption, clinical use, diagnostic use, or any therapeutic application.
Clinical trial record (13 studies)
Published, placebo-controlled human studies of this compound, in order. Each row reports what the study measured and what its abstract states. This is a description of the research record, not guidance for use.
| Year | Study | Design | What it found |
|---|---|---|---|
| 1996 | Chapman et al., J Clin Endocrinol Metab | 32 healthy adults aged 64-81; placebo, 2, 10 or 25mg once daily; 14- and 28-day periods | 25mg raised mean 24-hour GH 97% and IGF-1 from 141 to 265 µg/L by 4 weeks; fasting glucose rose 5.4 to 6.8 mmol/L; cortisol unchanged; prolactin +23% within normal range. |
| 1996 | Copinschi et al., J Clin Endocrinol Metab | 9 healthy young men; placebo, 5 or 25mg at bedtime; 7-day crossover | GH pulse frequency rose through added low-amplitude pulses; IGF-1 rose dose-dependently; 24-hour cortisol unchanged apart from timing. |
| 1997 | Copinschi et al., Neuroendocrinology | 8 young and 6 older adults; 2, 5 or 25mg at bedtime; 7- and 14-day periods | In the young, stage IV sleep +50% and REM +20%; in adults 65-71, REM +50% and shorter REM latency. |
| 1998 | Murphy et al., J Clin Endocrinol Metab | 8 volunteers on 18 kcal/kg/day; 25mg once daily for the last 7 of 14 days; crossover | Nitrogen balance +0.31 g/day on MK-677 against -1.48 g/day on placebo; IGF-1 restored. |
| 1998 | Svensson et al., J Clin Endocrinol Metab | 24 obese men; 25mg daily or placebo; 8 weeks | IGF-1 +40%; fat-free mass up; total and visceral fat unchanged; oral glucose tolerance impaired at 2 and 8 weeks. |
| 1999 | Murphy et al., J Bone Miner Res | 187 adults 65+ across three placebo-controlled studies of 2-9 weeks; 5-50mg | Bone resorption marker NTx +10-17% at 2 weeks; osteocalcin +29% at 9 weeks; IGF-1 +55-94%. |
| 2001 | Codner et al., Clin Pharmacol Ther | 18 prepubertal children with GH deficiency; 0.2 or 0.8mg/kg/day; 7-8 days | 0.8mg/kg raised peak GH, IGF-1 and IGFBP-3; no change in prolactin, glucose, thyroid hormones, cortisol or insulin. |
| 2004 | Bach et al., J Am Geriatr Soc | 161 hip-fracture patients 65+; 6 months daily; 13 centres | IGF-1 +84% vs +17% on placebo; no significant difference in functional performance measures. |
| 2008 | Nass et al., Ann Intern Med | 65 healthy adults 60-81; 25mg once daily; 2-year randomised crossover | Fat-free mass +1.1kg vs -0.5kg; visceral fat unchanged; fasting glucose +0.3 mmol/L and insulin sensitivity down; appetite, transient oedema and muscle pain; strength and function unchanged. |
| 2008 | Sevigny et al., Neurology | 563 patients with mild-to-moderate Alzheimer's; 25mg daily; 12 months | IGF-1 +60% at 6 weeks and +73% at 12 months; no effect on any of four clinical progression measures. |
| 2011 | Adunsky et al., Arch Gerontol Geriatr | 123 hip-fracture patients; 25mg daily; 24 weeks; phase IIb | IGF-1 +51 ng/mL; gait speed improved, most function measures did not; stopped early over a heart-failure signal in a small number of patients. |
| 2018 | Campbell et al., Nephrol Dial Transplant | 26 haemodialysis patients; 3-month randomised crossover | IGF-1 1.76-fold higher, a 65% greater increase than placebo; no serious adverse effects attributed to the drug. |
| 2022 | Bright & Thorner, Horm Res Paediatr (as LUM-201) | 68 children with GH deficiency; single-dose stimulation test within a randomised trial | Median peak GH 15.0 ng/mL after LUM-201 against 5.5 for standard diagnostic stimuli. |
MK-677 clinical trials: what 25 years of studies measured
RESEARCH USE ONLY — not for human or animal consumption. Not for diagnostic or therapeutic use.
Ingredients & Dosage
| MK-677 (Ibutamoren) | 15mg per tablet |
Inactive ingredients / formulation base
| Microcrystalline Cellulose | Filler |
| Magnesium Stearate | Flow agent |
SKU: MKT0900MG
Shipping & Storage
Shipping: Every order ships 2-Day — free on orders $150+, $4.99 otherwise. Orders placed before 3 PM PT on a business day dispatch the same day, and delivery is typically 2 business days after dispatch.
Storage: Store in a cool, dry place. Refrigeration recommended after opening for optimal stability. Keep away from direct sunlight.
Regulatory Statement
For laboratory and research use only. Not for human or animal consumption. This product is sold exclusively to qualified researchers and licensed laboratories.
This product is not a drug, food, or cosmetic, and is not for diagnostic or therapeutic use. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
A certificate of analysis (COA) is available for this product — view the published COA.
Why Research Peptides
All comparisons reflect general industry practices. Stemcode products are intended solely for laboratory research and are not for human consumption.
The Research Standard
All comparisons reflect general industry practices. Stemcode products are intended solely for laboratory research and are not for human consumption.
